Bloch Benjamin, Brown Sue, Angadi Darshan, Crawfurd Edward
Acta Orthop Belg. 2015 Jun;81(2):225-32.
We present the outcome of 270 cemented titanium alloy femoral stems. These patients were followed up annually both clinically and radiologically, and were included up until their last follow-up. 120 patients completed a 10-year follow-up. The 10-year survival of the Ultima Straight Stem cemented femoral component (defined by revision of the femoral stem) was 90.1% (95% CI=84.0-94.0%), with aseptic loosening being the major reason for failure. The preoperative Harris Hip Score improved from 35.3 to 79.3 at 10 years. There were 17 cases of stem subsidence, radiolucent lines in 11 hips, 5 cases of cement fracture and 18 hips had osteolysis in 2 adjacent Gruen zones. This is the largest study in the English literature of this implant, and reflects UK district general hospital practice with surgery performed by a variety of surgical grades and via different surgical approaches. Although the outcome of this implant was within the previous standard set by the National Institute for Health and Clinical Excellence and is comparable to other series of titanium stems, it is inferior to that of more modern cemented and uncemented implants, and falls outside the new NICE recommendation of <5% revision rate at ten year. As a result this implant is no longer used in our institution, and it has also now been withdrawn from the market. We suggest that patients with this implant should be followed up radiologically due to the relatively high rate of stem subsidence and lucency between the cement and prosthesis, to identify those who may be at risk of failure.
我们展示了270例骨水泥型钛合金股骨柄的治疗结果。这些患者每年都接受临床和放射学随访,直至最后一次随访均纳入研究。120例患者完成了10年的随访。Ultima Straight Stem骨水泥型股骨组件的10年生存率(根据股骨柄翻修定义)为90.1%(95%可信区间=84.0-94.0%),无菌性松动是主要的失败原因。术前Harris髋关节评分在10年时从35.3提高到79.3。有17例柄下沉,11髋出现透亮线,5例骨水泥骨折,18髋在相邻的2个Gruen区出现骨溶解。这是英文文献中关于该植入物的最大规模研究,反映了英国地区综合医院的实际情况,手术由不同手术级别医生通过不同手术入路进行。尽管该植入物的结果在英国国家卫生与临床优化研究所此前设定的标准范围内,且与其他系列钛柄相当,但它不如更现代的骨水泥型和非骨水泥型植入物,且未达到英国国家卫生与临床优化研究所新推荐的10年翻修率<5%的标准。因此,该植入物在我们机构已不再使用,现在也已退出市场。我们建议,由于柄下沉率和骨水泥与假体之间透亮线发生率相对较高,对于植入该植入物的患者应进行放射学随访,以识别那些可能有失败风险的患者。